Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Yuan Shi · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2020 · $390,000 — Project Summary Influenza A virus causes disease in 5-20% of the population with over 200,000 hospitalizations annually in US. The antigen drift and shift of influenza virus pose a serious challenge for flu vaccination program. Although IFN response is known as the first important host defending mec…
ALASDAIR C. STEVEN · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · 2020 · $362,643 — In a continuing collaboration with E. Freed (NCI), we analyzed the role of a conserved Pro-Pro-Ile-Pro (PPIP) motif (CA residues 122-125 in the loop connecting helices 6 and 7 of CA) in HIV-1 assembly. Prior data indicated that the mutations P122A and I124A impair release, infectivity, and replicati…
Steven M Wolinsky · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2020 · $562,516 — PROJECT SUMMARY The innate immune recognition of dengue virus infection triggers antiviral immune responses; however, there is little information about how the virus regulates these measures or how these responses affect dengue virus (DENV) disease pathogenesis and immunity. System biology approa…
Barney Graham · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $1,309,145 — While the outbreak of ZIKV in the Americas is likely to subside in the next 1-2 years, there is going to be an ongoing risk of congenital Zika syndrome in babies born to mothers exposed to ZIKV during pregnancy. There is no licensed vaccine or treatment to combat ZIKV infection. Because of the urgen…
FRANK J GONZALEZ · DIVISION OF BASIC SCIENCES - NCI · 2020 · $866,441 — Nonalcoholic steatohepatitis (NASH) is the progressive stage of nonalcoholic fatty liver disease that highly increases the risk of cirrhosis and liver cancer, and there are few therapeutic options available in the clinic. While virus-induced hepatitis has been sharply reduced with vaccine applicatio…
George N. Pavlakis · DIVISION OF BASIC SCIENCES - NCI · 2020 · $1,511,661 — An important goal of this project continues to be the generation and testing of maximally efficient expression vectors for specific antigens. Our hypothesis is that the DNA vaccine dose is suboptimal for many human applications; therefore, increased efficiency is necessary for practical human DNA va…
Ursula Buchholz · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $1,258,386 — We previously performed codon-pair deoptimization (CPD) of various open reading frames (ORFs) of RSV. This is done by rearranging codons using computer algorithms and de novo gene synthesis to increase the content of normally-underrepresented codon-pairs without changing amino acid coding or overall…
Jiang Zhu · INTERNATIONAL AIDS VACCINE INITIATIVE · 2020 · $292,223 — Project Summary Broadly neutralizing antibodies (bnAbs) recognize conserved epitopes on the envelope glycoprotein (Env) of the human immunodeficiency virus type-1 (HIV-1). Atomic structures of the BG505 SOSIP.664 gp140 trimer have provided a rational framework for Env-based HIV-1 vaccine design. …
Matthew Adrian Coleman · UNIVERSITY OF CALIF-LAWRNC LVRMR NAT LAB · 2020 · $361,476 — ABSTRACT Throughout the world Chlamydia trachomatis (Ct) is the most common sexually transmitted bacterial pathogen. In countries with poor sanitary conditions ocular infections with Ct can result in trachoma, the most frequent cause of preventable blindness worldwide. Based on protection and serolo…
paolo lusso · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $1,847,653 — The development of a protective and/or therapeutic HIV vaccine has been hampered by unprecedented challenges, primarily due to the unique properties of the HIV-1 envelope (Env) trimer, a cleverly engineered entry machinery that features an extraordinary assortment of immune-evasion tactics, includin…
Frederick Porter · DUKE UNIVERSITY · 2020 · $257,560 — Project 2: Current Good Manufacture Practices (CGMP) Production of Nucleoside-Modified mRNAs Encoding HIV-1 Envelopes This IPCAVD grant seeks to develop and evaluate mRNA as an HIV-1 vaccine platform. Project 2 will oversee the manufacture of two nucleoside-modified mRNAs by current good manufacturi…
Barton F. Haynes · DUKE UNIVERSITY · 2020 · $629,514 — The overall goal of the Animal Models Core is to support all programs of the IPCAVD by performing immunization studies in CH58 unmutated common ancestor (UCA) VH + VL knock-in (KI) mice and rhesus macaques, with ALVAC-C vCP2438 prime and modified mRNA encoding trivalent mosaic gp120s for induction o…
CHOWDA VENKATARAVAPPA · NEOVAXSYN, INC. · 2020 · $299,999 — Particle-Based Co-Delivery of HIV Immunogens as Next-Generation HIV Vaccines: A major focus of HIV vaccine research has been the development of immunogens that elicit broadly neutralizing antibody responses targeting the envelope protein (Env). While the field has predominantly focused on immunogen …
Peter Deak · UNIVERSITY OF CHICAGO · 2020 · $65,310 — Project Abstract: Dendritic cell (DC) antigen uptake and presentation is a crucial initial step in establishing adaptive immune responses. This project will characterize a small sub-set of DCs, called hyper-responder DCs, which display enhanced antigen uptake, immune activation and potentially initi…
Harvey Michael Friedman · UNIVERSITY OF PENNSYLVANIA · 2020 · $796,177 — Abstract A vaccine for prevention of genital herpes is a high public health priority. Herpes vaccines that performed well in rodents have not protected humans; therefore, novel approaches are needed. We propose the following: 1) Set a much higher bar for vaccine efficacy in animal models than used p…
Norbert Pardi · UNIVERSITY OF PENNSYLVANIA · 2020 · $609,757 — ABSTRACT Influenza virus is one of the most important human infectious diseases. The influenza mortality is estimated to be approximately 650,000 per year worldwide, in addition, occasional global pandemics can infect up to 20- 40% of the world's population. Licensed influenza virus vaccines require…
ANNE GOLDFELD · BOSTON CHILDREN'S HOSPITAL · 2020 · $270,500 — Ebola virus (EBOV) and Marburg virus (MARV) are highly lethal hemorrhagic fever viruses of the Filoviridae family of viruses. Currently, there are no effective oral or easily scalable therapies for either virus. Both EBOV and MARV manifest vigorous anti-host evasion strategies focused on blocking th…
Alejandro Castellanos-Gonzalez · UNIVERSITY OF TEXAS MED BR GALVESTON · 2020 · $237,000 — Project Summary/Abstract The World Health Organization reports diarrhea kills around 760,000 children under five every year. Cryptosporidium is a leading cause of diarrhea morbidity and mortality. Therefore novel treatments against this pathogen are urgently needed. The limitations of tools used to …
PAUL JOSEPH UTZ · STANFORD UNIVERSITY · 2020 · $842,000 — 7. Project Summary/Abstract The overarching goal of this New Aim 4 is to test the hypothesis that SARS-CoV-2 (CoV-2) causes autoimmune disease (AI) in a subset of infected patients. Our preliminary studies on 336 COVID-19 samples from 282 COVID19 patients (four COVID-19 cohorts in three geographical…
ANDREW W GRIMSON · CORNELL UNIVERSITY · 2020 · $400,213 — Project Summary /Abstract Neonates are highly susceptible to infection and respond poorly to vaccination for reasons that are not well understood. Based on our published data, we believe that neonates are particularly vulnerable to repeat infections because their naïve CD8+ T cells are intrinsically…